or Try an Advanced Search...

    Technical Analysis for VRDN - Viridian Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 15.40 5.62% 0.82
    VRDN closed up 5.62 percent on Friday, May 3, 2024, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 7
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical VRDN trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    New Uptrend Bullish 0.00%
    NR7 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    MACD Bullish Signal Line Cross Bullish 5.62%
    Wide Bands Range Expansion 5.62%
    Gapped Up Strength 5.62%
    Wide Bands Range Expansion 11.51%
    Older End-of-Day Signals for VRDN ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 2 days ago
    Up 1 ATR 2 days ago
    Gapped Up (Full) 2 days ago
    Rose Above 20 DMA 2 days ago
    Rose Above Previous Day's High 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    VRDN Chart by TradingView
    Basic chart:

    Profile

    Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado, with research and development operations in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biotechnology Biology Monoclonal Antibody Thyroid Eye Disease

    Is VRDN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 29 Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
    Mar 6 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Mar 5 Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
    Feb 29 Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations
    Feb 28 Viridian Therapeutics GAAP EPS of -$1.35
    Feb 27 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
    Feb 16 Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
    Jan 18 Viridian Therapeutics stock slides on pricing stock offering to raise $150 million
    Jan 18 Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
    Jan 17 Viridian Therapeutics starts public offering of common and preferred stock
    See more VRDN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 28.35
    52 Week Low 10.925
    Average Volume 929,321
    200-Day Moving Average 17.43
    50-Day Moving Average 16.75
    20-Day Moving Average 14.77
    10-Day Moving Average 13.78
    Average True Range 0.90
    RSI (14) 51.92
    ADX 26.89
    +DI 25.28
    -DI 24.73
    Chandelier Exit (Long, 3 ATRs) 14.62
    Chandelier Exit (Short, 3 ATRs) 14.91
    Upper Bollinger Bands 17.28
    Lower Bollinger Band 12.26
    Percent B (%b) 0.63
    BandWidth 34.00
    MACD Line -0.79
    MACD Signal Line -0.97
    MACD Histogram 0.1817
    Fundamentals Value
    Market Cap 919.83 Million
    Num Shares 59.7 Million
    EPS -5.14
    Price-to-Earnings (P/E) Ratio -3.00
    Price-to-Sales 3322.96
    Price-to-Book 7.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 16.14
    Resistance 3 (R3) 16.09 15.79 16.01
    Resistance 2 (R2) 15.79 15.61 15.82 15.97
    Resistance 1 (R1) 15.60 15.49 15.70 15.65 15.93
    Pivot Point 15.30 15.30 15.35 15.33 15.30
    Support 1 (S1) 15.11 15.12 15.21 15.16 14.87
    Support 2 (S2) 14.81 15.00 14.84 14.83
    Support 3 (S3) 14.62 14.81 14.79
    Support 4 (S4) 14.67